UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

Current opinion in pharmacology, 2008-08, Vol.8 (4), p.393-412

2008

Volltextzugriff (PDF)

The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway

Cancer research (Chicago, Ill.), 2004, Vol.64 (1), p.262-272

2004

Volltextzugriff (PDF)

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Molecular cancer therapeutics, 2011-02, Vol.10 (2), p.360-371

2011

Volltextzugriff (PDF)

An evaluation of the ability of pifithrin-α and -β to inhibit p53 function in two wild-type p53 human tumor cell lines

Molecular cancer therapeutics, 2005-09, Vol.4 (9), p.1369-1377

2005

Volltextzugriff (PDF)

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Clinical cancer research, 2012-10, Vol.18 (20), p.5650-5661

2012

Volltextzugriff (PDF)

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Clinical cancer research, 2012-07, Vol.18 (14), p.3912-3923

2012

Volltextzugriff (PDF)

AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth

Molecular cancer therapeutics, 2010-05, Vol.9 (5), p.1100-1110

2010

Volltextzugriff (PDF)

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon Cancer models

JNCI : Journal of the National Cancer Institute, 2003-11, Vol.95 (21), p.1624-1633

2003

Volltextzugriff (PDF)

Sports Injuries of the Hand and Wrist

1st ed. 2019., 2019

Volltextzugriff (PDF)

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

Cancer research (Chicago, Ill.), 2020-04, Vol.80 (8), p.1735-1747

2020

Volltextzugriff (PDF)

Abstract 2384: Investigating mechanisms of tolerance to APOBEC3B upregulation in cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2384-2384

2020

Volltextzugriff (PDF)

Abstract 293: Screening the druggable genome for synthetic lethal interactions with the CHK1 inhibitor PNT737

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.293-293

2017

Volltextzugriff (PDF)

Abstract 4418: Autophagy induction contributes to cisplatin resistance in ovarian cancer and is independent of AKT pathway activity

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4418-4418

2015

Volltextzugriff (PDF)

Sports Injuries of the Elbow

2020

Volltextzugriff (PDF)

Abstract 4481: First report of preclinical pharmacology of two novel potent AKT inhibitors and development of pharmacodynamic (PD) biomarkers in tumor and surrogate tissue

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4481-4481

2010

Volltextzugriff (PDF)

Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.27-27

2010

Volltextzugriff (PDF)

An evaluation of the ability of pifithrin-a and -b to inhibit p53 function in two wild-type p53 human tumor cell lines

Molecular cancer therapeutics, 2005-09, Vol.4 (9), p.1369-1377

2005

Volltextzugriff (PDF)

The contemporary drug development process: advances and challenges in preclinical and clinical development

Progress in cell cycle research, 2003, Vol.5, p.145

2003

Volltextzugriff (PDF)

Biomechanics of the Elbow Joint

Sports Injuries of the Elbow, 2020, p.23-35

2020

Volltextzugriff (PDF)

Osteochondritis Dissecans of the Elbow

Sports Injuries of the Elbow, 2020, p.63-72

2020

Volltextzugriff (PDF)

The Stiff Painful Elbow in the Athlete

Sports Injuries of the Elbow, 2020, p.73-82

2020

Volltextzugriff (PDF)

Clinical Anatomy of the Elbow

Sports Injuries of the Elbow, 2020, p.1-13

2020

Volltextzugriff (PDF)

Rehabilitation

Sports Injuries of the Elbow, 2020, p.109-120

2020

Volltextzugriff (PDF)

1 – 25 von 233

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(197)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(233)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

An evaluation of the ability of pifithrin-α and -β to inhibit p53 function in two wild-type p53 human tumor cell lines

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon Cancer models

Sports Injuries of the Hand and Wrist

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

Abstract 2384: Investigating mechanisms of tolerance to APOBEC3B upregulation in cancer

Abstract 293: Screening the druggable genome for synthetic lethal interactions with the CHK1 inhibitor PNT737

Abstract 4418: Autophagy induction contributes to cisplatin resistance in ovarian cancer and is independent of AKT pathway activity

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

Sports Injuries of the Elbow

Abstract 4481: First report of preclinical pharmacology of two novel potent AKT inhibitors and development of pharmacodynamic (PD) biomarkers in tumor and surrogate tissue

Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma

An evaluation of the ability of pifithrin-a and -b to inhibit p53 function in two wild-type p53 human tumor cell lines

The contemporary drug development process: advances and challenges in preclinical and clinical development

Biomechanics of the Elbow Joint

Osteochondritis Dissecans of the Elbow

The Stiff Painful Elbow in the Athlete

Clinical Anatomy of the Elbow

Rehabilitation

Suchergebnisse filtern